An Open Label, Randomized, Parallel Groups, Bioequivalence Study to Compare a Single Oral Dose of GSK372475B or GSK372475C in Male and Female Healthy Volunteers.
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2012
At a glance
- Drugs NS 2359 (Primary)
- Indications Attention-deficit hyperactivity disorder; Depression
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline
- 29 Nov 2007 Status changed from recruiting to completed.
- 15 Aug 2007 Status changed from initiated to recruiting.
- 09 Jul 2007 New trial record.